459 related articles for article (PubMed ID: 9399600)
21. Atorvastatin.
Wierzbicki AS
Expert Opin Pharmacother; 2001 May; 2(5):819-30. PubMed ID: 11336625
[TBL] [Abstract][Full Text] [Related]
22. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
Bianchi S; Bigazzi R; Caiazza A; Campese VM
Am J Kidney Dis; 2003 Mar; 41(3):565-70. PubMed ID: 12612979
[TBL] [Abstract][Full Text] [Related]
23. Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?
Athyros VG; Tziomalos K; Karagiannis A; Wierzbicki AS; Mikhailidis DP
Curr Opin Cardiol; 2010 Jul; 25(4):406-10. PubMed ID: 20375883
[TBL] [Abstract][Full Text] [Related]
24. Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia.
Jayaram S; Prasad HB; Sovani VB; Langade DG; Mane PR
J Indian Med Assoc; 2007 Mar; 105(3):142-5, 150. PubMed ID: 17824470
[TBL] [Abstract][Full Text] [Related]
25. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
26. Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study.
Panichi V; Manca-Rizza G; Paoletti S; Taccola D; Consani C; Sbragia G; Mantuano E; Marchetti V; Carpi A; Barsotti G
Biomed Pharmacother; 2006 Jun; 60(5):249-52. PubMed ID: 16740374
[TBL] [Abstract][Full Text] [Related]
27. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
Alaupovic P; Heinonen T; Shurzinske L; Black DM
Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
Stern RH; Yang BB; Hounslow NJ; MacMahon M; Abel RB; Olson SC
J Clin Pharmacol; 2000 Jun; 40(6):616-23. PubMed ID: 10868312
[TBL] [Abstract][Full Text] [Related]
29. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
Wlodarczyk J; Sullivan D; Smith M
Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019
[TBL] [Abstract][Full Text] [Related]
30. [Atorvastatin (Lipitor)].
Carpentier Y; Ducobu J; Sternon J
Rev Med Brux; 1999 Oct; 20(5):427-33. PubMed ID: 10582478
[TBL] [Abstract][Full Text] [Related]
31. [Lowering cholesterol. New concepts with atorvastatin].
Internist (Berl); 1997 Jan; 38(1 Suppl):1-8. PubMed ID: 9102396
[No Abstract] [Full Text] [Related]
32. Atorvastatin--a new lipid-lowering drug.
Med Lett Drugs Ther; 1997 Mar; 39(997):29-31. PubMed ID: 9121394
[No Abstract] [Full Text] [Related]
33. [HMG-CoA-reductase inhibitors: a new principle in the treatment of hypercholesterolemia].
Saxenhofer H; Weidmann P
Ther Umsch; 1990 Jun; 47(6):509-13. PubMed ID: 2375007
[TBL] [Abstract][Full Text] [Related]
34. [Atorvastatin].
Kajinami K; Takekoshi N
Nihon Rinsho; 2001 Mar; 59 Suppl 3():598-604. PubMed ID: 11347138
[No Abstract] [Full Text] [Related]
35. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins.
Romero R; Calviño J; Rodriguez J; Sánchez-Guisande D
Nephrol Dial Transplant; 2000 Sep; 15(9):1446-9. PubMed ID: 10978406
[TBL] [Abstract][Full Text] [Related]
36. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
Nawrocki JW; Weiss SR; Davidson MH; Sprecher DL; Schwartz SL; Lupien PJ; Jones PH; Haber HE; Black DM
Arterioscler Thromb Vasc Biol; 1995 May; 15(5):678-82. PubMed ID: 7749881
[TBL] [Abstract][Full Text] [Related]
37. Atorvastatin attenuates inflammatory infiltration and vascular remodeling in lung of hypercholesterolemia rabbits.
Duan S; Zhang Y; Wu SJ; Jiang LZ; Zhang J; Gan Y; Chen P; Zhao SP; Li GY
Exp Lung Res; 2010 Dec; 36(10):573-92. PubMed ID: 21043990
[TBL] [Abstract][Full Text] [Related]
38. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves.
Jiménez-Alonso J; Osorio JM; Gutiérrez-Cabello F; López de la Osa A; León L; Mediavilla García JD
Arch Intern Med; 1999 Aug 9-23; 159(15):1811-2. PubMed ID: 10448788
[No Abstract] [Full Text] [Related]
39. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
Lea AP; McTavish D
Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
[TBL] [Abstract][Full Text] [Related]
40. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
Fujita R; Matsushima T
Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
